Display Settings:

Format

Send to:

Choose Destination
    Rev Med Suisse. 2006 Mar 15;2(57):738-40, 743-5.

    [Infectious risks of immunomodulating therapies in rheumatology].

    [Article in French]

    Source

    Service des maladies infectieuses, Département de médecine, HUG, 1211 Genève 14. Christian.vandelden@hcuge.ch

    Abstract

    Corticosteroids and cytotoxic drugs form the conventional immunomodulators in rheumatology. This therapeutic arsenal has recently been widened by TNF-alpha antagonists and other anti-cytokines. If rheumatoid arthritis is itself associated with infections, immunomodulating therapies further increase the risk of infection, especially when used in combination therapies. Among conventional therapies, corticosteroids are associated with the highest risk for both common bacterial and opportunistic infections. Infliximab is the TNF-alpha antagonist associated with the highest risk of infection. Its use has been particularly associated with cases of severe tuberculosis. All patients at risk for tuberculosis, treated with corticosteroids or TNF-alpha antagonists, should therefore receive an adequate prophylaxis.

    PMID:
    16604876
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk